TOP TEN perturbations for 39653_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39653_at
Selected probe(set): 204354_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39653_at (204354_at) across 6674 perturbations tested by GENEVESTIGATOR:
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):4.6481705Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):3.7414522Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-3.6521635Number of Samples:2 / 2
| Experimental | zalypsis study 2 |
| OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
| Control | untreated OPM1 cell sample |
| OPM1 multiple myeloma cells untreated. |
T-cell isolation study 11 / T-cell isolation study 6
Relative Expression (log2-ratio):-2.972683Number of Samples:2 / 2
| Experimental | T-cell isolation study 11 |
| CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20°C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population. | |
| Control | T-cell isolation study 6 |
| CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population. |
colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)
Relative Expression (log2-ratio):2.6494207Number of Samples:24 / 3
| Experimental | colorectal cancer study 4 (recurring) |
| LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery. | |
| Control | adjacent colon tissue (recurring) |
| Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up. |
colorectal cancer study 4 (non-recurring) / adjacent colon tissue (non-recurring)
Relative Expression (log2-ratio):2.2224693Number of Samples:76 / 18
| Experimental | colorectal cancer study 4 (non-recurring) |
| LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients did not develop metastatic recurrence during follow-up after surgery. | |
| Control | adjacent colon tissue (non-recurring) |
| Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). No metastatic recurrence during follow-up. |
house dust mite study 2 (allergic) / house dust mite study 2 (non-allergic)
Relative Expression (log2-ratio):-2.201129Number of Samples:5 / 4
| Experimental | house dust mite study 2 (allergic) |
| Primary nasal epithelial cells from subjects with monotypical allergy to house dust mite (HDM) were exposed to house dust mite extract (2µg/ml) for 24 hours. Subjects (19-55 years old) were selected based on skin prick test for HDM and other common allergens. The subjects had refrained from using any medication for their allergy in the 4 weeks before the samples collection. Nasal biopsies for isolation of primary cells were taken from the lower edge of the inferior turbinate, and 2 cm from the anterior end. | |
| Control | house dust mite study 2 (non-allergic) |
| Primary nasal epithelial cells from healthy subjects with no allergies were exposed to house dust mite (HDM) extract (2µg/ml) for 24 hours. Subjects (21-32 years old) were selected based on skin prick test for HDM and other common allergens. Nasal biopsies for isolation of primary cells were taken from the lower edge of the inferior turbinate, and 2 cm from the anterior end. |
precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (late relapse; >24m)
Relative Expression (log2-ratio):2.1007242Number of Samples:7 / 8
| Experimental | precursor-B-ALL study 7 (PDX; long-term; >10wk) |
| Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis). | |
| Control | precursor-B-ALL study 7 (late relapse; >24m) |
| Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse after 24 months from diagnosis (late relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457. |
glioma study 27 (glioblastoma, NOS) / glioma study 27 (pilocytic astrocytoma)
Relative Expression (log2-ratio):2.0862026Number of Samples:4 / 2
| Experimental | glioma study 27 (glioblastoma, NOS) |
| Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma). | |
| Control | glioma study 27 (pilocytic astrocytoma) |
| Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma). |
colorectal cancer study 25 / adjacent colon tissue
Relative Expression (log2-ratio):2.067543Number of Samples:94 / 17
| Experimental | colorectal cancer study 25 |
| Human primary colorectal carcinoma sample. | |
| Control | adjacent colon tissue |
| Normal colon tissue samples adjacent to tumor from patients with colorectal cancer. |